A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC
← catalyst calendarSponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 1
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
175actual
Sites
41
Countries
Austria, Belgium, Poland +6
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2018-12-27 | actual | When the study began enrolling |
| Primary completion | 2023-05-23 | actual | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2026-07-01 | estimated | The whole study's end, after follow-up |
| First posted | 2019-01-28 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-05-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Metastatic Non-Small Cell Lung Cancer (NSCLC)
Interventions
- Drug: Durvalumab — also filed as MEDI4736
- Drug: Danvatirsen — also filed as AZD9150
- Drug: Oleclumab — also filed as MEDI9447
- Drug: MEDI5752
- Drug: Pemetrexed
- Drug: Carboplatin
- Drug: Gemcitabine
- Drug: Cisplatin
- Drug: Nab-paclitaxel
- Drug: AZD2936
Primary outcome
what the primary-completion date above is the date OFAssessment of AEs by CTCAE v5.0
measured From informed consent until the safety follow-up visit 3 months after the last dose of study drug, or until the final data cut-off (DCO) date, whichever is earlier.
Publications
- PMID 41380462 — linked by the registry
Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed